SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as traders split between those viewing recent price action as a technical breakout opportunity and long-term skeptics who remain wary of its historical performance and lack of confirmed high-profile partnerships. The conversation is driven by a mix of market-wide altcoin momentum, renewed interest in Japan-based blockchain narratives, and speculative anticipation regarding the project's evolving ecosystem.

TOSHI

TOSHI is seeing a surge in community engagement as investors speculate on potential exchange listings and its role as a key asset within the Base network ecosystem. Enthusiasts are actively accumulating tokens, citing favorable chart patterns and historical performance as reasons for their growing optimism.

Abercrombie & Fitch Co. engages in the retail of apparel, personal care products, and accessories. The firm operates through following geographical segments: Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific (APAC). Its brands include Abercrombie and Hollister. The company was founded by David Abercrombie in 1892 and is headquartered in New Albany, OH.

Abercrombie & Fitch Co. - Ordinary Shares - Class A

Abercrombie & Fitch Co.

Abercrombie & Fitch ($ANF) is experiencing intense market volatility as investors weigh robust earnings beats and aggressive share buyback programs against concerns regarding tariff-related headwinds and cautious guidance. The stock remains a focal point for community discussion, with traders closely debating its low P/E valuation, the potential for short squeezes, and the company's ability to maintain momentum amidst a shifting retail landscape.

Spitcoin is a community-driven cryptocurrency built on the Solana blockchain that powers a decentralized creator economy through the LimitlessFlo platform.  The project focuses on giving creators full control over their content and earnings by enabling instant monetization from day one—through tips, subscriptions, live streaming, and marketplace transactions—without the restrictions of traditional platforms like bans, algorithm suppression, or delayed payouts.  At its core, Spitcoin is about combining meme culture with real utility, creating a self-sustaining ecosystem where platform activity drives token demand, and token usage fuels platform growth.

SpitCoin

SpitCoin is gaining momentum as the community highlights its utility as the powering technology behind the Limitlessflo platform. Investors are actively discussing the token alongside WAGMI, viewing both as emerging projects with significant growth potential.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market volatility and active investor debate as it approaches its earnings report, with sentiment split between those bullish on the company's long-term expansion into AI and logistics and those concerned about consumer spending habits and high valuations. The community is heavily focused on the stock's recent price swings and whether the platform can maintain its growth narrative amidst stiff competition and broader economic pressures.

GIGA is a meme token deployed on the Solana blockchain intended to honor the legend Ernest Khalimov the original “Gigachad”, by utilizing the strength of memes and “Chad” energy.  GIGA is a community run project.

GigaChad

GigaChad is seeing renewed market attention and high social media engagement as investors highlight its cultural persistence and long-term community dedication. The community is buzzing over its recent expansion into consumer health products, fueling active discussions about its potential for long-term growth as a major memecoin contender.

Hormuz Toll Fund (HTF) is a community-driven SPL token deployed on the Solana blockchain. The project takes its name and visual identity from the Strait of Hormuz, the maritime corridor through which a significant share of global seaborne crude oil transits, and adopts an energy and shipping-toll motif as the basis for its branding and community culture. Despite the word "Fund" in its name, HTF is not an investment fund, security, or pooled investment vehicle, and the project holds no physical commodity, oil contracts, or shipping rights of any kind. It is not affiliated with any government, maritime authority, or shipping entity. The token follows the standard Solana SPL fungible token model and trades on Solana-native decentralized exchanges with all transfers and balances publicly verifiable on-chain.

Hormuz Toll Fund

Hormuz Toll Fund is gaining traction as traders speculate on the project's long-term utility and potential for higher time frame growth.

LCX.com is a platform that innovates capital markets by providing solutions for compliant digital assets and security tokens. It is a secure and compliant platform for buying, selling, transferring, and storing digital currency.

LCX is generating significant community discourse as investors debate its long-term potential versus concerns over regulatory hurdles, exchange performance, and perceived lack of transparency. While some users are aggressively accumulating during price pullbacks and highlighting upcoming catalysts like MiCA approvals and RWA initiatives, others remain skeptical about the project's viability and market sentiment.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is attracting significant attention as investors monitor its lead drug candidate, ivonescimab, which is undergoing an FDA BLA review with a decision expected later this year. The community remains highly focused on the company's clinical pipeline and upcoming ASCO presentation, with many viewing the stock's recent volatility as a consolidation phase before potentially impactful regulatory and trial milestones.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is experiencing heavy bearish sentiment and community frustration, with many users labeling it a "pump and dump" and questioning its long-term viability given its significant year-to-date losses. While some investors remain focused on the 15% APY staking rewards as a potential long-term play, the broader community discourse is dominated by disappointment over the token's inability to decouple from Bitcoin's volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celcuity (CELC) to Release Earnings on Wednesday

Celcuity (NASDAQ:CELC) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 13. (View Earnings Report at...

Celcuity, Inc. (NASDAQ:CELC) Given Consensus Rating of "Moderate Buy" by Analysts

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issu...

Best Biotech Stocks To Research - May 4th

Celcuity, Danaher, Vertex Pharmaceuticals, Rallybio, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies focused on developing biological products, drugs, diagnostics, or platform technologies...

Citizens Jmp Increases Celcuity (NASDAQ:CELC) Price Target to $160.00

Citizens Jmp increased their price target on shares of Celcuity from $150.00 to $160.00 and gave the stock a "market outperform" rating in a report on Monday...

Celcuity (NASDAQ:CELC) Reaches New 12-Month High on Analyst Upgrade

Celcuity (NASDAQ:CELC) Hits New 52-Week High on Analyst Upgrade...

"Just Another Dip Investors Will Buy": Futures Drop, Oil Rises On Renewed Iran Tension

"Just Another Dip Investors Will Buy": Futures Drop, Oil Rises On Renewed Iran Tension

 US futures whipsawed and crude oil spiked higher as tensions flared up again in the Middle East, taking the focus off a run of strong earnings by megacap tech companies. As of 8:00am ET, S&P and...

Needham & Company LLC Raises Celcuity (NASDAQ:CELC) Price Target to $157.00

Needham & Company LLC increased their price target on Celcuity from $122.00 to $157.00 and gave the company a "buy" rating in a report on Monday...

<ul class="summary-bullets"><li>H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised its price target to $165 from $94, citing positive Phase 3 trial results.</li><li>Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating.</li><li>The firm highlighted expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.</li></ul>Celcuity Inc. (CELC) could become an acquisition target in the oncology space, according to analysts, after the company reported positive results in the Phase 3 trial of its breast cancer therapy.According to TheFly, analysts at HC Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy, gedatolisib, achieved its primary endpoint in a Phase 3 trial.<a href="https://stocktwits.com/symbol/CELC">Celcuity shares</a> were up more than 15% in Monday’s pre-market trade, extending the gains from Friday. If CELC stock ends Monday’s regular trading session with these gains, it would be the stock’s best single-day gain in more than six months.Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Why Are Analysts Optimistic?</h2>Analysts at H.C. Wainwright upgraded Celcuity to ‘Buy’ from ‘Neutral’ and raised their price target to $165 from $94, citing positive Phase 3 trial results. The firm said gedatolisib has the potential to be a “game-changing” treatment for HR+/HER2- advanced breast cancer and could position Celcuity as an acquisition target.Citizens raised its price target for Celcuity to $160 from $150 and maintained an ‘Outperform’ rating. The firm said the data suggest the drug could expand its use in second-line ER+/HER2- advanced breast cancer, demonstrating benefit regardless of PI3K mutation status.It also pointed to expected progression-free survival of 11–12 months for the triplet regimen and stronger-than-anticipated efficacy from the doublet versus control.Stifel analyst Stephen Willey raised the firm’s price target on Celcuity to $150 from $125 and maintained a ‘Buy’ rating. Willey said the “statistically significant and clinically meaningful” improvement in the Phase 3 trial was largely expected, but noted that its selection as a late-breaking oral presentation at the ASCO Annual Meeting on June 2 was the bigger surprise.<h2 class="st-heading-2">Celcuity’s Latest Announcement</h2>Celcuity reported positive Phase 3 results for gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer after prior CDK4/6 and aromatase inhibitor treatment.The company stated that the gedatolisib triplet regimen met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival compared with alpelisib plus fulvestrant.The gedatolisib doublet also delivered a statistically significant PFS benefit compared with the control arm, despite being a secondary endpoint; both regimens demonstrated manageable safety profiles with no new safety concerns.HR+/HER2- breast cancer is the most common form of the disease, representing about 70% of all cases. Within this group, roughly 40% of patients carry PIK3CA mutations.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> is up 26% year-to-date and 1,063% over the past 12 months. The Tema Oncology ETF (CANC) is up 50% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 58%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gamestop-ryan-cohen-ebay-build-larger-business-gme-ebay-stock/cZQMpRjReJc">GameStop's Ryan Cohen Says He Plans On Bringing An Entrepreneurial Mindset To eBay And Building Something 'Much Larger'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Wall Street Believes Celcuity Could Become An Acquisition Target – Why This Analyst Raised Their Price Target By A Whopping 76%

H.C. Wainwright expressed optimism about the company’s prospects after Celcuity’s breast cancer therapy achieved its primary endpoint in a Phase 3 trial.

Equity

Why Is Celcuity Stock Rallying Today?

Celcuity stock rises after Phase 3 VIKTORIA-1 trial meets endpoint, showing PFS gains in breast cancer and setting up FDA filing.read more...

Best Biotech Stocks To Watch Today - May 3rd

Danaher, Moderna, Vertex Pharmaceuticals, Celcuity, and Oruka Therapeutics are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies focused on developing, manufacturing, or commercializing biological or medical...

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.05	--	--	N/A
Q4 '25	-$1.04	-$0.97	6.92%	BEAT
Q3 '25	-$1.02	-$0.92	9.68%	BEAT
Q2 '25	-$0.88	-$1.04	-17.61%	MISSED
Q1 '25	-$0.86	-$0.86	0.19%	BEAT

CELC
Celcuity Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CELC News

CELCCelcuity Inc